Shou-Ching Tang

5PUBLICATIONS
25CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Molecular targetsPredictive and prognostic markers
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (5)

|Aug 20, 2026
Pathologic Complete Response (pCR) Rate and Predictors of Response to Taxane, Trastuzumab, and Pertuzumab in HER2‑Positive Breast Cancer: Secondary Analyses of EA1181/CompassHER2 pCR.

|Oct 13, 2022
The race to develop oral SERDs and other novel estrogen receptor inhibitors: recent clinical trial results and impact on treatment options.

Yating Wang, Shou-Ching Tang

|Feb 24, 2022
Validity of 1% Hormonal Receptor Positivity Cutoff by the ASCO/College of American Pathologists Guidelines at the Georgia Cancer Center.

Firas Kreidieh, Ramses F Sadek, Li Fang Zhang

|Feb 10, 2022
Anti-HER2 therapy in metastatic breast cancer: many choices and future directions.

Carrie S Wynn, Shou-Ching Tang

|Apr 12, 2021
Systemic toxicities of trastuzumab-emtansine predict tumor response in HER2+ metastatic breast cancer.

Shou-Ching Tang, Carter L Capra, Germame H Ajebo

Pageof 1

Frequent Collaborators

1 joint publications

Firas Kreidieh

1 joint publications

Ramses F Sadek

1 joint publications

Reena Patel

1 joint publications

Hiral S Patel